EyePoint Pharmaceuticals, Inc.
EYPT
$14.52
$0.836.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 204.02M | 255.73M | 318.19M | 370.91M | 253.79M |
| Total Receivables | 1.05M | 625.00K | 442.00K | 607.00K | 378.00K |
| Inventory | 2.11M | 2.68M | 2.13M | 2.31M | 2.81M |
| Prepaid Expenses | 8.03M | 4.64M | 4.82M | 8.08M | 10.27M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 899.00K | 1.57M | 1.40M | 1.41M | 1.30M |
| Total Current Assets | 216.11M | 265.25M | 326.98M | 383.31M | 268.55M |
|
|
|||||
| Total Current Assets | 216.11M | 265.25M | 326.98M | 383.31M | 268.55M |
| Net Property, Plant & Equipment | 29.52M | 29.85M | 29.55M | 29.18M | 29.80M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 6.07M | 6.05M | 6.03M | 5.98M | 2.57M |
| Total Assets | 251.70M | 301.15M | 362.56M | 418.47M | 300.92M |
|
|
|||||
| Total Accounts Payable | 10.08M | 19.69M | 16.42M | 11.72M | 7.34M |
| Total Accrued Expenses | 17.88M | 11.40M | 18.10M | 17.96M | 13.89M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 1.96M | 1.90M | 1.77M | 1.25M | 1.19M |
| Total Finance Division Other Current Liabilities | 176.00K | 191.00K | 5.39M | 18.12M | 26.38M |
| Total Other Current Liabilities | 176.00K | 191.00K | 5.39M | 18.12M | 26.38M |
| Total Current Liabilities | 30.09M | 33.18M | 41.68M | 49.05M | 48.79M |
|
|
|||||
| Total Current Liabilities | 30.09M | 33.18M | 41.68M | 49.05M | 48.79M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 21.30M | 21.82M | 22.31M | 21.86M | 21.92M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 118.00K | 148.00K | 177.00K | 11.06M | 11.47M |
| Total Liabilities | 51.51M | 55.14M | 64.17M | 81.96M | 82.18M |
|
|
|||||
| Common Stock & APIC | 1.24B | 1.22B | 1.22B | 1.21B | 1.05B |
| Retained Earnings | -1.04B | -977.64M | -918.21M | -873.02M | -831.62M |
| Treasury Stock & Other | 919.00K | 832.00K | 923.00K | 1.03M | 1.17M |
| Total Common Equity | 200.18M | 246.01M | 298.40M | 336.50M | 218.73M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 200.18M | 246.01M | 298.40M | 336.50M | 218.73M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 200.18M | 246.01M | 298.40M | 336.50M | 218.73M |
|
|
|||||